(Q80087467)
Statements
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies (English)
Sharma RA
Steward WP
Daines CA
Knight RD
O'Byrne KJ
Dalgleish AG
8 August 2006